spacer
home > ict > winter 2008 > pharma champion
PUBLICATIONS
International Clinical Trials

Pharma Champion

CDISC and other standards groups have continued to have an influence on the pharmaceutical industry, writes Mark Penniston at Omnicare Clinical Research

CDISC PROGRESS REPORT

Since its founding, the Clinical Data Interchange Standards Consortium (CDISC) has grown to an international standard organisation with user groups established in multiple worldwide locations. It is a major champion in the pharmaceutical industry for its work in developing platformindependent data standards for the electronic acquisition and exchange of clinical trial data and metadata. As with any organisation of multiple members, lively discussion continues between individual members and their volunteers. The agreement generated by these discussions is probably a factor in the reason why the community has been adapting these standards, and the importance in understanding the efficiencies gained from using them.

Eighteen of the top 20 pharmaceutical companies and eight of the top 10 clinical research organisations (CROs) are currently members of CDISC (1). Since 2000, membership has grown over 600 per cent, with membership renewal rates greater than 88 per cent (2). Additionally, many vendors with supportive tool sets have appeared in the market place, stating their support for the elements of these standards. Membership has grown internationally, particularly in both Europe and the Pacific Rim.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Mark Penniston, MS, is Vice President of Global Biometrics and Clinical Writing. With a focus on delivering expert service excellence and quality results, Mark brings over 20 years of industry experience to this business. A strong proponent of standardisation and CDISC, Mark led Omnicare Clinical Research to join CDISC in 2004 for the purpose of harmonising internal processes around these globally-recognised definitions.
spacer
Mark Penniston
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Turkish Cargo keeps growing in the first quarter of 2019

Maintaining its accomplished operations from Ataturk and Istanbul airports as "Dual Hub", the global brand of Turkish Cargo continued its strong growth momentum during the first quarter of the year despite the shrinkage of the global air cargo sector.
More info >>

White Papers

Clinical Trials in Russia Orange Paper: 2nd Quarter 2014

Synergy Research Group

The Ministry of Health of Russian Federation approved 194 new clinical trials of all types including local and bioequivalence studies during the 2nd Quarter of 2014 (3% less than at the same period of the last year). The main contribution to the total number of studies was made by multinational multi-center clinical trials (MMCT) and the number of these studies stayed the same as in Q2 2013 – 81 studies. The number of bioequivalence studies (BE) decreased from 76 studies in Q2 2013 to 59 in Q2 2014, a 22% decrease from last year’s figure. The number of local clinical trials (LCT) increased from 42 in Q2 2013 to 54 clinical trials in Q2 2014.
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement